Drug Interactions with Chemotherapeutic Agents in Veterinary Oncology: A Practical Guide

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Concurrent use of NSAIDs with platinum agents (e.g., cisplatin) or doxorubicin necessitates vigilant renal function monitoring (serum creatinine, urea, urine protein-to-creatinine ratio) due to potential for additive nephrotoxicity and reduced renal clearance.
• Doxycycline has demonstrated in vitro antagonism with doxorubicin and paclitaxel, and a biphasic interaction with cisplatin, suggesting caution and consideration of alternative antibiotics to avoid compromised chemotherapy efficacy.
• Corticosteroids can variably affect cyclophosphamide metabolism, potentially altering efficacy or toxicity, and may induce apoptosis in lymphoid cells, theoretically reducing the efficacy of other cytotoxic agents targeting dividing cells.
• Antibiotics that compete for renal tubular secretion, such as penicillins, can delay methotrexate clearance, increasing the risk of toxicity, particularly with high-dose protocols.
• P-glycoprotein inhibitors (e.g., ketoconazole, some macrolides) can increase central nervous system penetration of vinca alkaloids and doxorubicin, elevating the risk of neurotoxicity and cardiotoxicity.
• Additive myelotoxicity is a significant concern when combining bone marrow suppressive agents, requiring enhanced monitoring of complete blood counts with manual differentials to detect neutropenia and thrombocytopenia.

Cancer patients in veterinary practice rarely receive a single drug. Chemotherapy is commonly combined with antiemetics, analgesics, antimicrobials, and supportive care agents, and many patients continue long-term medications for comorbid conditions. Each addition carries the potential to alter the efficacy or toxicity of the cytotoxic agent. This article reviews clinically significant drug interactions involving chemotherapeutic agents, with emphasis on NSAIDs, corticosteroids, and antibiotics, and provides a decision framework for the practicing veterinarian. The focus is on dogs and cats, with reference to other species where relevant. The goal is to help clinicians anticipate interactions, adjust monitoring, and avoid combinations that compromise treatment outcomes.

The evidence base for veterinary chemotherapy interactions is thin. Much of what is known derives from human oncology, in vitro studies, and extrapolation from related drug classes. Where data are absent or contested, this is stated explicitly. Clinicians should consult current formularies and product labels for dosing and contraindication details, as recommendations change with new evidence.

At a Glance

Mechanisms of Chemotherapy Drug Interactions

Drug interactions in oncology operate through pharmacokinetic and pharmacodynamic pathways. Pharmacokinetic interactions alter drug absorption, distribution, metabolism, or excretion. Pharmacodynamic interactions occur when two drugs act on the same physiologic pathway, producing additive, synergistic, or antagonistic effects that do not depend on changes in drug concentration.

Cytochrome P450 enzymes, particularly CYP3A4 in humans and its orthologs in animals, metabolize many chemotherapeutic agents, including vinca alkaloids, taxanes, and cyclophosphamide. Drugs that induce or inhibit these enzymes can change chemotherapy exposure substantially. P-glycoprotein, an efflux transporter encoded by the MDR1 gene, limits the intracellular accumulation of several cytotoxic drugs and is also expressed at the blood-brain barrier. Inhibitors of P-glycoprotein, such as ketoconazole and some macrolide antibiotics, can increase the penetration of vincristine and doxorubicin into the central nervous system, raising the risk of neurotoxicity and cardiotoxicity.

The bone marrow microenvironment also influences drug response. Stromal cells within the marrow can protect leukemic cells from chemotherapy through direct contact and soluble factors, a mechanism that may explain resistance in acute myeloid leukemia and that has implications for combination therapy design A role for the bone marrow microenvironment in drug resistance of acute myeloid leukemia. This stromal protection is not a drug interaction in the conventional sense, but it affects how combination regimens should be sequenced and monitored.

NSAIDs and Chemotherapy

Cyclooxygenase-2 is overexpressed in several solid tumors, including hepatocellular carcinoma, and COX-2 inhibition has been explored as an adjunct to chemotherapy Cyclooxygenase-2 in hepatocellular carcinoma. The rationale is sound: COX-2 derived prostaglandins promote tumor growth, angiogenesis, and immune evasion, and inhibiting them may enhance the effects of cytotoxic agents. In practice, however, the combination of NSAIDs and chemotherapy requires careful risk assessment.

The principal concerns are additive nephrotoxicity and gastrointestinal injury. Cisplatin is eliminated by the kidneys and is itself nephrotoxic. Concurrent NSAID use reduces renal blood flow through prostaglandin inhibition, which can impair cisplatin clearance and potentiate renal injury. Doxorubicin also causes gastrointestinal toxicity, and NSAIDs increase the risk of ulceration and bleeding. For patients receiving these agents, NSAIDs should be used at the lowest effective dose for the shortest duration, with periodic assessment of renal function and gastrointestinal signs.

The evidence for synergistic antitumor activity when NSAIDs are combined with chemotherapy is largely preclinical. In vitro and animal model data suggest that COX-2 inhibitors may enhance the effects of certain cytotoxic drugs, but clinical validation in veterinary patients is lacking. The decision to combine an NSAID with chemotherapy should therefore be driven by the need for analgesia or anti-inflammatory effect, not by an expectation of improved tumor response.

Corticosteroids and Cytotoxic Agents

Corticosteroids are common in veterinary oncology, both as components of chemotherapy protocols and as supportive therapy for nausea, inflammation, and peritumoral edema. Their interactions with cytotoxic drugs are complex and dose dependent.

Cyclophosphamide is a prodrug that requires hepatic activation. Corticosteroids can induce the enzymes responsible for this activation, potentially increasing the formation of active metabolites and toxic byproducts. The clinical significance of this interaction is uncertain, and some protocols deliberately combine cyclophosphamide with prednisone. The timing of administration may matter. In human studies, the sequence of corticosteroid and cyclophosphamide administration has influenced both efficacy and toxicity, but comparable veterinary data are not available.

Corticosteroids also induce apoptosis in lymphoid cells, which is the basis for their use in lymphoma protocols. When combined with cytotoxic agents that target dividing cells, the corticosteroid-induced cell cycle arrest may reduce the efficacy of the cytotoxic drug. This is a theoretical concern, and clinical protocols that combine these agents have demonstrated efficacy. The practical implication is that corticosteroids should not be added casually to a chemotherapy protocol without considering whether they alter the intended mechanism of action.

Antibiotics and Chemotherapy

Antimicrobials are frequently prescribed to oncology patients for prophylaxis or treatment of infection. Several clinically relevant interactions have been identified.

Doxycycline has been studied in combination with common chemotherapeutic agents in a human breast cancer cell line. The combination of doxycycline with doxorubicin or paclitaxel produced therapeutic antagonism at all effect levels, and the G2/M arrest characteriztic of doxorubicin treatment was abrogated when doxycycline was added Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells. The combination with cisplatin produced a biphasic interaction: near additive at low doses and synergistic at higher doses. These findings are from a single in vitro study and cannot be extrapolated directly to veterinary patients, but they suggest that doxycycline should be used with caution in patients receiving doxorubicin or paclitaxel.

Methotrexate is actively secreted by the renal tubules, and drugs that compete for this pathway, including penicillins and some other antibiotics, can delay its clearance and increase toxicity. This interaction is well documented in human medicine and is relevant to veterinary patients receiving high-dose methotrexate protocols. The risk is greatest with concurrent administration, and separation of dosing times may not fully eliminate the interaction because of prolonged renal excretion.

Aminoglycosides and cisplatin are both nephrotoxic and ototoxic. Concurrent use produces additive injury, and this combination should be avoided unless no alternative exists. If it is necessary, renal function and urinary output should be monitored closely.

Natural Health Products and Chemotherapy

Owners frequently administer supplements and natural health products to cancer patients. These products can sensitize cancer cells to chemotherapy in experimental models, but they can also interact with cytotoxic drugs in unpredictable ways Natural health products and natural compounds as therapeutic agents for the treatment of cancer. The major hurdle is the lack of clinical validation and the absence of standardized formulations. Clinicians should ask owners specifically about supplement use and should be cautious about recommending products that have not been studied in veterinary patients. The potential for antioxidant supplements to interfere with the oxidative mechanisms of drugs such as doxorubicin is a particular concern, although clinical data are lacking.

Clinical Assessment Sequence for Suspected Interactions

When a veterinary patient receiving chemotherapy develops unexpected toxicity or loss of efficacy, a structured assessment distinguishes true drug interactions from disease progression, dosing errors, or organ dysfunction. Begin by compiling a complete medication list, including owner-administered over-the-counter products, supplements, and topical preparations. Many owners do not volunteer this information, and natural health products are frequently omitted from the history despite their capacity to alter chemotherapy disposition and effect Natural Health Products and Natural Compounds as Therapeutic Agents for the Treatment of Cancer.

Next, establish the temporal relationship between drug administration and the observed change. Interactions that follow enzyme induction develop over days to weeks, whereas competitive protein binding or renal clearance competition produces effects within hours of co-administration. Document the chemotherapy protocol, the dose actually administered, and the route. Verify that the correct vial or concentration was used, particularly when multiple drugs are prepared in the same treatment session.

Assess organ function relevant to the drugs involved. Hepatic and renal profiles, complete blood count, and urinalysis provide the baseline against which toxicity is judged. For drugs with narrow therapeutic indices, such as doxorubicin and vincristine, measure the relevant organ function immediately before each dose. If an interaction is suspected, repeat the assessment at the time of the adverse event instead of relying on pre-treatment values.

Finally, grade the toxicity using a standardized scale and determine whether the reaction is dose-limiting. This distinction matters because a grade 1 neutropenia may be acceptable within a protocol, whereas a grade 4 neutropenia after the first cycle demands investigation. Document the reaction in the medical record with the suspected interacting drug, the mechanism, and the management steps taken.

Decision Points That Change Management

The first decision point is whether the interacting drug can be discontinued. For NSAIDs, corticosteroids, and antibiotics, this is often feasible when the indication is adjunctive instead of essential. An NSAID given for mild osteoarthritis pain can usually be withdrawn during chemotherapy, whereas an antibiotic treating an active infection cannot.

The second decision point is whether the interaction is pharmacokinetic or pharmacodynamic. Pharmacokinetic interactions alter drug concentration through changes in absorption, distribution, metabolism, or excretion. Pharmacodynamic interactions alter the drug effect at the target site without changing concentration. The distinction guides monitoring: pharmacokinetic interactions warrant therapeutic drug monitoring where available, while pharmacodynamic interactions warrant closer clinical and laboratory observation.

The third decision point is the timing of administration. Some interactions are sequence-dependent. Cyclophosphamide used before adoptive immunotherapy enhances antitumor activity, but the same drug given after effector cells may suppress the desired response Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer. When an interaction is suspected to be sequence-dependent, separate the administrations by at least 24 to 48 hours where the clinical situation permits.

The fourth decision point is dose modification. When an interacting drug cannot be avoided, reduce the chemotherapy dose by one level and escalate cautiously if toxicity does not recur. Consult the current formulary and label references for dose adjustment guidance, as recommendations vary by drug, species, and protocol.

Monitoring Parameters and Their Detection Value

The table reflects monitoring parameters that are clinically useful across species, but the specific reference intervals and action thresholds vary by species and laboratory. Consult the MSD Veterinary Manual for species-specific reference values and interpret results in the context of the individual patient.

Documentation and Communication

Record the suspected interaction in the medical record with the following elements: the chemotherapy agent, the interacting drug, the mechanism category, the observed effect, the temporal relationship, and the management action taken. Include the grade of toxicity and the outcome. This documentation supports future treatment decisions for the same patient and contributes to the practice's pharmacovigilance data.

Communicate the interaction risk to the owner in writing. Provide a list of drugs and supplements to avoid during the treatment period, and instruct the owner to contact the practice before administering any new medication, including over-the-counter products. This is particularly important for natural health products, which have demonstrated the ability to sensitize cancer cells to chemotherapy in experimental models but remain poorly characterized in terms of clinical drug interactions Natural Health Products and Natural Compounds as Therapeutic Agents for the Treatment of Cancer. The absence of clinical validation means the risk of an unanticipated interaction is real, and the safest approach is to avoid these products during active chemotherapy unless a specific benefit is documented.

Species and Production System Considerations

The correct management of a suspected interaction differs by species. In dogs and cats, the clinician has latitude to discontinue or substitute interacting drugs and to adjust chemotherapy doses. In food animals, the constraints are different. Chemotherapeutic agents are rarely used in production species, but when they are, the withdrawal period implications and the absence of established protocols require consultation with regulatory guidance from the FDA Center for Veterinary Medicine and the WOAH terrestrial animal health standards. Extralabel use of chemotherapy in food animals carries substantial regulatory risk, and the interaction management framework described here assumes a companion animal context unless stated otherwise.

Equine patients present a middle ground. Chemotherapy is used for sarcoids, lymphomas, and other neoplasms, and the same interaction principles apply. However, the larger body mass and the practical constraints of repeated dosing mean that monitoring intervals may need adjustment. The AVMA practice resources provide general guidance on professional practice standards that apply across species, but specific chemotherapy protocols for horses are less standardized than for dogs and cats.

Patient status changes the correct choice at every decision point. A patient with pre-existing renal disease facing a cisplatin and NSAID interaction has fewer safe options than a patient with normal renal function. A patient with hepatic insufficiency metabolizing cyclophosphamide through the cytochrome P450 system will be more sensitive to enzyme-inducing or enzyme-inhibiting drugs. The assessment sequence must therefore begin with a complete organ function profile, not with the interaction itself.

The evidence base for many chemotherapy drug interactions in veterinary patients is extrapolated from human studies or from in vitro work. The interaction between doxycycline and doxorubicin, for example, was characterized in a human breast cancer cell line, where the combination produced therapeutic antagonism and abrogated the doxorubicin-induced cell cycle arrest Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells. Whether this antagonism occurs in canine or feline patients is unknown. The prudent approach is to assume the interaction may occur and to monitor accordingly, while acknowledging that the clinical significance in veterinary patients has not been established.

Recognized Complications and Early Detection

The most consequential failure mode in veterinary oncology is the delayed recognition of enhanced myelotoxicity from additive or synergistic drug combinations. When a patient receiving doxorubicin develops fever after the addition of an NSAID, the differential must include both drug-induced neutropenia and sepsis, and the diagnostic sequence matters. A complete blood count with manual differential should be performed before any antipyretic is administered, because masking fever with an NSAID in a neutropenic patient can obscure the earliest sign of bacteremia. Serial hematology every 48 to 72 hours during the nadir period detects the decline before clinical signs appear, and a rising band neutrophil count with a falling total neutrophil count is the earliest laboratory signature of impending sepsis.

Hepatotoxicity from combined CYP450 inhibition presents more insidiously. A patient on vincristine that begins an azole antifungal may show no clinical change for 7 to 14 days, then present with anorexia and icterus. Serial serum bile acids and alanine aminotransferase measured at each chemotherapy visit detect the trend before bilirubin rises. Alkaline phosphatase rises later and is less specific. The discriminating finding is a doubling of alanine aminotransferase from the pre-azole baseline, which warrants dose reduction or discontinuation of the interacting drug instead of the chemotherapy.

Nephrotoxicity from combined cisplatin and NSAID therapy is detected earliest through urine specific gravity and symmetric dimethylarginine, not serum creatinine. A specific gravity that falls below 1.020 in a dog with previously concentrated urine precedes azotaemia by days. Once serum creatinine rises, irreversible tubular injury is already established. Serial urine protein-to-creatinine ratios distinguish prerenal from renal protein loss, and a doubling of the ratio in a patient on both agents mandates discontinuation of the NSAID.

Common Errors and Corrective Actions

The most frequent error is the assumption that a drug interaction requires simultaneous administration. Many interactions, particularly those involving enzyme induction or inhibition, persist for days to weeks after the interacting drug is withdrawn. A patient that completed a course of doxycycline 5 days before doxorubicin may still show altered doxorubicin clearance, because the tetracycline effect on cell cycle kinetics and drug transport persists beyond its elimination half-life. The corrective action is to review the complete medication history for the preceding 30 days, also the current prescription list.

A second error is the failure to distinguish pharmacodynamic from pharmacokinetic interactions when predicting toxicity. Two drugs that both prolong the QT interval, such as a vinca alkaloid and a macrolide antibiotic, produce additive cardiotoxicity that no dose adjustment of either drug alone will fully prevent. The corrective action is to obtain a baseline electrocardiogram before the second agent is added and to repeat it at the expected peak effect of the combination.

A third error is the reflexive discontinuation of chemotherapy when an interaction is suspected. Many interactions are manageable through dose reduction, schedule alteration, or enhanced monitoring. Discontinuing a cytotoxic agent in a patient with responsive disease converts a manageable risk into a guaranteed treatment failure. The corrective action is to quantify the interaction risk, implement the appropriate monitoring, and continue therapy with adjusted parameters.

Limitations of the Evidence and Divergent Expert Opinion

The evidence base for chemotherapy drug interactions in veterinary patients is largely extrapolated from human cell lines, rodent models, and human case series. In vitro findings do not always translate to clinical effect. The antagonism observed when doxycycline is combined with doxorubicin or paclitaxel in human breast adenocarcinoma cells, attributed to abrogation of the G2/M arrest, has not been reproduced in a controlled veterinary clinical trial, and its relevance to canine or feline patients is uncertain. Some oncologists therefore continue to prescribe doxycycline concurrently with doxorubicin when treating suspected tick-borne disease, while others insist on a washout period. Both positions are defensible given the available data.

Expert opinion also diverges on the management of NSAID use during metronomic chemotherapy. The theoretical benefit of COX-2 inhibition in tumors that express the enzyme, supported by evidence that COX-2 signaling contributes to hepatocarcinogenesis and that COX-2 inhibitors suppress tumor cell growth in vitro, is balanced against the risk of gastrointestinal and renal toxicity. Some specialists recommend continuous NSAID coverage throughout metronomic protocols, others restrict NSAIDs to the peri-chemotherapy window, and a third group avoids them entirely. No prospective veterinary study has resolved this disagreement.

The bone marrow microenvironment adds another layer of uncertainty. Evidence from acute myeloid leukemia research indicates that stromal cells protect leukemic stem cells from chemotherapy through direct contact and metabolic signaling, which suggests that drugs affecting the microenvironment could either enhance or impair chemotherapy efficacy depending on the target. Whether this applies to solid tumors in veterinary patients is unknown.

Referral, Consultation, and Reporting

Referral to a veterinary oncologist is warranted when a suspected interaction produces grade 3 or grade 4 toxicity, when a patient requires an interacting drug combination for which no published safety data exist, or when dose adjustment of a cytotoxic agent is needed in a patient with pre-existing organ dysfunction. A clinical pharmacologist or veterinary teaching hospital laboratory should be consulted when therapeutic drug monitoring is required, particularly for drugs with narrow therapeutic indices where the interaction is suspected to alter clearance.

Adverse drug event reporting to the FDA Center for Veterinary Medicine is appropriate for any suspected interaction that results in death, hospitalization, or significant disability. Reporting contributes to the detection of interactions that are too rare to appear in clinical trials. For antimicrobial interactions, stewardship principles from the AVMA antimicrobial use resources should guide whether an antimicrobial is necessary at all, because eliminating an unnecessary interacting drug is safer than managing its consequences. International movement of patients or products may trigger additional considerations under WOAH terrestrial animal health standards, particularly for food-producing animals where withdrawal period adjustments may be required.

Frequently Asked Questions

How should I adjust my monitoring plan when a patient on chemotherapy also needs an NSAID for osteoarthritis?

The decision to combine an NSAID with a cytotoxic agent requires a documented risk assessment. Renal and gastrointestinal toxicity are the primary concerns, so baseline and serial assessments of creatinine, urea, and uric acid are warranted. Gastrointestinal protectants should be considered when the chemotherapy agent carries significant emetic or mucositic potential. The COX-2 pathway is implicated in tumor growth in some cancers, which raises theoretical concerns about NSAID effects on treatment efficacy, but clinical evidence in veterinary patients is limited. Document the indication, the expected duration of NSAID therapy, and the monitoring schedule in the medical record. If renal function deteriorates, discontinue the NSAID before modifying the chemotherapy protocol.

What practical steps reduce interaction risk when the practice lacks therapeutic drug monitoring equipment?

When assays for drug levels are unavailable, rely on clinical surrogates and temporal separation. Administer drugs with known or suspected interactions at different times of day where pharmacokinetic data support this approach. Serial complete blood counts, biochemistry panels, and urinalysis provide indirect evidence of drug accumulation or enhanced toxicity. For example, a deeper or prolonged neutrophil nadir after adding an interacting drug suggests altered clearance. The FDA Center for Veterinary Medicine maintains labeling information that may specify administration intervals or food effects relevant to absorption. Contact a veterinary clinical pharmacologist or oncology service for guidance when the interaction is poorly characterized and monitoring options are limited.

Does the interaction profile differ between dogs and cats for common cytotoxic drugs?

Yes, species differences in drug metabolism and excretion are clinically significant. Cats have reduced glucuronidation capacity, which alters the disposition of several drugs and can change the magnitude of an interaction. Doxorubicin clearance and toxicity profiles differ between dogs and cats, and concurrent medications that inhibit or induce hepatic enzymes may therefore have species-specific consequences. The MSD Veterinary Manual provides species-specific pharmacology notes that should be consulted before combining agents. Extrapolating interaction data from dogs to cats, or from human literature to either species, is unreliable. When species-specific data are absent, state that uncertainty explicitly in the medical record and choose monitoring intervals that err toward earlier and more frequent assessment.

How do I document a suspected drug interaction for the medical record and for regulatory reporting?

Record the suspected interacting drugs, their doses, routes, and administration times, plus the temporal relationship to the observed adverse event. Include baseline and post-event laboratory values, physical examination findings, and any interventions performed. Describe the severity and outcome using standard adverse event terminology where available. For products approved for veterinary use, suspected adverse drug events can be reported through the FDA Center for Veterinary Medicine adverse event reporting pathway. Distinguish between a confirmed interaction, a probable interaction, and a coincidental finding. This distinction matters for future treatment decisions and for cumulative pharmacovigilance data. Keep the documentation objective and avoid speculative mechanism statements unless they are supported by published evidence.

How should I explain a chemotherapy drug interaction risk to a client who is administering multiple medications at home?

Use concrete language that names the specific drugs and the specific risk. Avoid abstract terms like "interaction" without explaining what it means for the animal. State which medications must be given at which times, which signs should prompt a call, and who to contact after hours. Provide a written medication schedule that includes the chemotherapy drug, all supportive medications, and any over-the-counter products the client has mentioned. Ask the client to bring all medication containers to every visit, including supplements, because natural health products can alter chemotherapy efficacy and toxicity. Confirm the client's understanding by asking them to repeat the schedule back. Document that the discussion occurred and what instructions were given.

What should I do when a client insists on continuing a supplement that has a theoretical interaction with the prescribed chemotherapy?

Acknowledge the client's interest in supportive care, then separate theoretical risk from documented harm. Some natural products have shown selective anticancer activity and can sensitize cancer cells to chemotherapy in experimental models, but clinical validation remains limited and drug interactions are poorly characterized. Offer a structured compromise: request the product name, manufacturer, and dose, then check the available literature for known interactions with the specific chemotherapy agent. If no interaction data exist, state that uncertainty plainly. Propose a washout period before chemotherapy administration where feasible, or schedule the supplement at a time distant from chemotherapy infusion. If the client declines to discontinue the product, document the discussion, the client's decision, and the monitoring plan. Referral to a veterinary oncologist is appropriate when the interaction risk is substantial and the client is unwilling to modify the regimen.

Related Clinical & Scientific Guides

• Veterinary Formulary Essentials: Navigating Drug References
• Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy
• Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review

References and Further Reading

• Natural Health Products (NHP's) and Natural Compounds as Therapeutic Agents for the Treatment of Cancer, Mechanisms of Anti-Cancer Activity of Natural Compounds and Overall Trends.. 2020.
• A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia.. 2021.
• Cyclooxygenase-2 in hepatocellular carcinoma.. 2006.
• Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells.. 2009.
• Gemcitabine-loaded gold nanospheres mediated by albumin for enhanced anti-tumor activity combining with CT imaging.. 2018.
• Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer.. 2001.
• FDA Center for Veterinary Medicine: Animal Drug Information. FDA CVM.
• AVMA Antimicrobial Use and Stewardship. American Veterinary Medical Association.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.

Related Articles

• Drug Interactions in Veterinary Oncology: Managing Polypharmacy
• Drug Interactions with Antithrombotic and Antiplatelet Agents in Veterinary Patients
• Drug Interactions with Immunosuppressive Agents in Veterinary Patients: Cyclosporine, Azathioprine, and More
• Drug Interactions with Antiviral Agents in Veterinary Patients: Current Knowledge and Gaps
• Drug Interactions with Antihypertensive Medications in Veterinary Patients

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.